BioCryst Pharmaceuticals Inc (NASDAQ:BCRX)
| 4.02 Delayed Data As of Sep 18 |  +0.03 / +0.75%Today’s Change | 1.38 Today|||52-Week Range 6.29 | +16.52% Year-to-Date |
Latest BCRX News | Press Releases
| BioCryst Pharmaceuticals, Inc. (BCRX) Investor Presentation - Slideshow Sep 15 / Seeking Alpha - Paid Partner Content | BioCryst Pharmaceuticals up 12% premarket on orphan drug tag for BCX9930 Aug 31 / Seeking Alpha - Paid Partner Content |
| U.S. Government to purchase additional RAPIVAB from Biocryst for ~$7M Sep 03 / Seeking Alpha - Paid Partner Content |
Today’s Trading
| Previous close | 3.99 |
| Today’s open | 3.91 |
| Day’s range | 3.90 - 4.04 |
| Volume | 272,583 |
| Average volume (3 months) | 7,607,310 |
| Market cap | $665.7M |
Data as of 3:59pm ET, 09/18/2020
Growth & Valuation
| Earnings growth (last year) | +4.00% |
| Earnings growth (this year) | +0.59% |
| Earnings growth (next 5 years) | +19.86% |
| Revenue growth (last year) | +136.45% |
| P/E ratio | NM |
| Price/Sales | 8.17 |
| Price/Book | 15.19 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| IMGNImmunoGen Inc | -0.03 | -0.73% |
| WVEWAVE Life Sciences L... | +0.44 | +2.30% |
| CARACara Therapeutics In... | -0.27 | -1.83% |
| TLRYTilray Inc | -0.09 | -1.66% |
Data as of 4:00pm ET, 09/18/2020
Financials
| Next reporting date | November 10, 2020 |
| EPS forecast (this quarter) | -$0.25 |
| Annual revenue (last year) | $48.8M |
| Annual profit (last year) | -$108.9M |
| Net profit margin | -222.99% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Durham, North Carolina |
Forecasts
